ARTICLE | Company News
Boehringer continues fibrosis drive via acquisition of Enleofen assets
January 10, 2020 12:52 AM UTC
The acquisition of Enleofen’s preclinical IL-11 inhibition platform is the latest in a string of deals by Boehringer to build out its fibrosis tool kit, giving the German pharma therapies against a new target for the indication.
Enleofen Bio Pte. Ltd. is eligible for more than $1 billion per product from Boehringer Ingelheim GmbH in upfront and development and commercial milestone payments. Additional financial terms are undisclosed...
BCIQ Target Profiles